Paul Jank
Has grant
Head of Translational Research Laboratory
Research Interests
Explore related searches
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
About
Paul Jank is the Head of the Translational Research Laboratory at Universitätsklinikum Marburg Pathologie in Germany. His research primarily focuses on breast cancer, colorectal carcinomas, and the molecular mechanisms underlying tumor behavior and response to therapies. Recent publications include studies on PIK3CA mutations in breast cancer and the diagnostic potential of insulinoma-associated protein 1 in colorectal cancer. He also investigates therapeutic targets and signaling pathways in circulating tumor cells and has developed new models for evaluating cancer treatments.
Recent Grants
Grant: Close
Identification of new prognostic tissue-based spatial biomarker profiles and quality-of-life aspects for patients with invasive-lobular breast cancer (ILC)
Open Date:
Close Date:
Articles (10)
Year:
2024
Year:
2023
Complementary to synaptophysin and chromogranin A, insulinoma‐associated protein 1 (INSM1) has emerged as a sensitive marker for the diagnosis of neuroendocrine neoplasms. Since there are no comparative data regarding INSM1 expression in conventional colorectal adenocarcinomas (CRCs) and colorectal mixed adenoneuroendocrine carcinomas/neuroendocrine carcinomas (MANECs/NECs), we examined INSM1 in a large cohort of conventional CRCs and MANECs/NECs. In conventional CRC, we put a special focus on conventional CRC with diffuse expression of synaptophysin, which carry the risk of being misinterpreted as a MANEC or a NEC. We investigated INSM1 according to the immunoreactive score in our main cohort of 1,033 conventional CRCs and 21 MANECs/NECs in comparison to the expression of synaptophysin and chromogranin A and correlated the results with clinicopathological parameters and patient survival. All MANECs/NECs expressed INSM1, usually showing high or moderate expression (57% high, 34% moderate, and 9% low), which distinguished them from conventional CRCs, which were usually INSM1 negative or low, even if they diffusely expressed synaptophysin. High expression of INSM1 was not observed in conventional CRCs. Chromogranin A was negative/low in most conventional CRCs (99%), but also in most MANECs/NECs (66%). Comparable results were observed in our independent validation cohorts of conventional CRC ( n = 274) and MANEC/NEC ( n = 19). Similar to synaptophysin, INSM1 expression had no prognostic relevance in conventional CRCs, while true MANEC/NEC showed a highly impaired survival in univariate and multivariate analyses (e.g. disease‐specific survival: p < 0.001). MANECs/NECs are a highly aggressive variant of colorectal cancer, which must be reliably identified. High expression of INSM1 distinguishes MANEC/NEC from conventional CRCs with diffuse expression of the standard neuroendocrine marker synaptophysin, which do not share the same dismal prognosis. Therefore, high INSM1 expression is a highly specific/sensitive marker that is supportive for the diagnosis of true colorectal MANEC/NEC.
Year:
2023
Year:
2023
Year:
2022
Year:
2022
Year:
2021
Year:
2021
Year:
2021
Year:
2021
Collaborators (10)
Anja E. Hauser
-
Konrad Klinghammer
charité university hospital
Juliana Gonçalves
Technical University of Munich
Christine Solbach
Goethe University Frankfurt
Judith Lea Lindner
-
Moritz Jesinghaus
-
Kristina Schwamborn
Technical University of Munich
Thomas Karn
Goethe University Frankfurt
Ingeborg Tinhofer-Keilholz
Charité - Universitätsmedizin Berlin
Andreas H. Mahnken
University Hospital
Make your next move.
Prepare your application
Review drafts before you send them.